Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.
Bobby C LiawChe-Kai TsaoSonia SengTomi JunYixuan GongMatthew D GalskyWilliam K OhPublished in: The oncologist (2022)
In this small series, one-third of mCRPC patients responded to platinum-based chemotherapy. Peripheral blood biomarker measurement is feasible in mCRPC, though the biomarkers we investigated were not associated with platinum response. Other biomarkers, such as DNA damage repair mutations, should be evaluated.
Keyphrases
- dna damage
- peripheral blood
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- oxidative stress
- prognostic factors
- peritoneal dialysis
- study protocol
- randomized controlled trial
- dna repair
- locally advanced
- high resolution
- phase ii
- atomic force microscopy
- single molecule
- open label
- high speed